NCT05974839Completed
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study
Source: ClinicalTrials.gov · Last updated 26 Sept 2024
Brief summary (registry, in English)
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 732 (actual)
- First submitted
- 18 Jul 2023
- Start date
- 1 Oct 2023
- Primary completion date
- 28 Feb 2024
- Lead sponsor
- State University of New York at Buffalo
- Diseases
- Multiple sclerosis
- NCT number
- NCT05974839
What you commit to
- Study type: Observational
- Participants enrolled: 732
- From 1 Oct 2023 to the primary completion date, 28 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- None
Who the study is looking for
- Patient participating in the ORATORIO study
- MRI scans available at baseline
- Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 2D/3D T1-WI at baseline
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Buffalo Neuroimaging Analysis Center Coordinator of this site? Confirm its status | Buffalo | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.